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Introduction
Partum-related hemorrhage is the leading cause of morbidity
and mortality among pregnant women resulting in 140,000
deaths each year.1 Although the majority of these deaths occur
in low income countries, excessive bleeding at delivery is also
frequent in high resource countries. In Australia, Canada and
the US, 3-7% of deliveries in 2005 were complicated by pri-
mary postpartum hemorrhage.2
The bleeding risk is expected to be higher in women with
inherited thrombocytopenias (ITs) because of low platelet
counts and associated defects of platelet function in some dis-
orders. Nevertheless, few studies have investigated this topic
and there is little evidence to guide management of pregnancy
and delivery.3 Fetal and neonatal outcomes are also not well-
described. 
One of the forms of IT most investigated with respect to
pregnancy is biallelic Bernard-Soulier Syndrome (bBSS), proba-
bly because of its early identification in the middle of the last
century. A systematic review of the literature published in 2010
identified 16 relevant articles, all case reports, describing 30
deliveries in 18 bBSS women.4 Excessive bleeding occurred in
18 cases of which blood transfusion was required in 15. All
women survived, but 2 required emergency hysterectomy.
Concerning the fetus, there was one intra-uterine death caused
by gastrointestinal bleeding and one neonatal death due to
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Pregnancy in women with inherited thrombocytopenias is a major matter of concern as both the mothers and the
newborns are potentially at risk of bleeding. However, medical management of this condition cannot be based on
evidence because of the lack of consistent information in the literature. To advance knowledge on this matter, we
performed a multicentric, retrospective study evaluating 339 pregnancies in 181 women with 13 different forms of
inherited thrombocytopenia. Neither the degree of thrombocytopenia nor the severity of bleeding tendency wors-
ened during pregnancy and the course of pregnancy did not differ from that of healthy subjects in terms of miscar-
riages, fetal bleeding and pre-term births. The degree of thrombocytopenia in the babies was similar to that in the
mother. Only 7 of 156 affected newborns had delivery-related bleeding, but 2 of them died of cerebral hemorrhage.
The frequency of delivery-related maternal bleeding ranged from 6.8% to 14.2% depending on the definition of
abnormal blood loss, suggesting that the risk of abnormal blood loss was increased with respect to the general pop-
ulation. However, no mother died or had to undergo hysterectomy to arrest bleeding. The search for parameters
predicting delivery-related bleeding in the mother suggested that hemorrhages requiring blood transfusion were
more frequent in women with history of severe bleedings before pregnancy and with platelet count at delivery
below 50 x 109/L.   
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ABSTRACT
antepartum intracranial hemorrhage. On this basis, it has
been concluded that bBSS is associated with a very high risk
of serious bleeding in the mother and the neonate.
Some information on pregnancy outcome is available
also for MYH9-related disease (MYH9-RD), one of the most
frequent forms of IT. A recent review of the literature exam-
ined 25 case reports and one case series describing a total of
75 pregnancies in 40 women.5 Postpartum hemorrhage in
the mother occurred in 4 cases, while no obvious bleeding
complications were reported among the newborns. Based
on these data, MYH9-RD does not seem to increase bleed-
ing risk either in mothers or neonates.
Limited data on pregnancy outcomes have been provided
for patients with mild to moderate thrombocytopenia due
to monoallelic BSS (mBSS), in all cases induced by the
p.Ala156Val substitution in GPIb alpha (Bolzano mutation).6
Overall, 20 women delivered 34 children with no excessive
maternal or neonatal bleeding. Although the authors did
not provide information on management of pregnancies
and childbirths, this study suggests that women with mBSS
have gestational outcomes similar to healthy subjects.
A moderate risk of bleeding during delivery has been
reported in a series of subjects with thrombocytopenia
induced by ANKRD26 mutations (ANKRD26-related
thrombocytopenia, ANKRD26-RT).7 Thirteen patients gave
birth, either vaginally or by caesarean section, with bleed-
ing complications in 3 women. No information was provid-
ed on prophylactic treatment or neonatal outcomes.
The paucity of evidence presently available, therefore,
indicates that maternal and neonatal bleeding risk during
pregnancy and delivery may vary with different forms of
IT, ranging from very severe to very mild. However, the evi-
dence concerns only four ITs and largely derives from case
reports or series of patients not specifically investigated
with respect to pregnancy. 
To remedy this scarcity of information, we performed a
retrospective, multicentric study aimed at systematically
collecting and analyzing pregnancy outcomes in a large
series of patients with well-defined forms of IT.
Methods
Patients
This study was promoted by the Scientific Working Group on
Thrombocytopenias and Platelet Function Disorders of the
European Hematology Association (EHA) and was announced at
the 2013 EHA Congress in Stockholm. Clinical centers that, based
on scientific publications and/or personal knowledge, represent
points of reference for ITs were invited to participate. Forty-five
institutions took part in the study. They were asked to analyze
their databases and extract data on pregnancies in women with
ITs. A series of questions had to be answered for each enrolled case
related to the base-line characteristics of the mother, the course of
pregnancy, and the management and outcome of delivery, with
particular attention to the bleeding events in the mother and the
newborn. 
Only women with diagnoses confirmed by genetic analysis
were eligible for the study. As an exception, positivity of the
immunofluorescence test for MYH9-related disease (MYH9-RD)
was considered sufficient for making the diagnosis in patients
where mutational screening was not available because of its very
high sensitivity and specificity.8
Neonates for whom genetic screening was not available were
considered affected from the same illness as the mother whenever
they were thrombocytopenic and the mother had a dominant dis-
order. In case of recessive disorders, documentation that the par-
ents were carriers of the disease was required. 
The Institutional Review Board of the IRCCS Policlinico San
Matteo Foundation of Pavia, Italy, approved the study protocol.
The study was performed in accordance with the Declaration of
Helsinki, and each center complied with local ethical rules.
Classification of bleeding
Because of the retrospective nature of the study, it was not pos-
sible to use the most recent bleeding scores that are most suited to
patients with primary hemostasis defects. Spontaneous bleeding
tendency in the mother before pregnancy was, therefore measured
by the World Health Organization bleeding scale: grade 0 indicates
no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3,
gross blood loss; grade 4, debilitating blood loss.9
The amount of blood loss has been used by most authors to
identify post-partum hemorrhages.10 However, this parameter was
available for only a few patients, and we could not use it.
Therefore, we identified two definitions for excessive bleeding at
delivery: “excessive bleedings requiring blood transfusion” (EBBT),
based on transfusion of platelets and/or red blood cells during or
after delivery to treat bleeding (prophylactic platelet transfusions
prior to delivery were not considered for definition of EBBT), and
“all excessive bleedings” (AEB), which includes not only patients
receiving platelets and/or red blood cells, but also subjects who did
not receive blood products and were judged by the treating physi-
cian as presenting larger than normal blood loss. Thus, EBBT is a
narrow definition that is expected to identify the most serious
blood loss, while AEB is a broader definition that also encompasses
less severe bleedings.
The same criteria were used to define increased bleedings with
previous surgery. Any type of bleeding in newborns was consid-
ered abnormal and recorded. Miscarriage was defined as sponta-
neous expulsion from the uterus of the products of conception
before viability. Pre-term birth was defined as live birth of a
neonate of less than 37 weeks gestational age. Platelet count was
measured by cell counters available in each center. 
Statistical analysis
Data were described as median and 25th-75th percentiles if contin-
uous and as counts if categorical. EBBT and AEB incidence and
95% confidence intervals (95%CI) were computed. Generalized
linear regression models were used to compare platelet counts
between and within groups; Huber-White robust standard errors
were calculated to account for intra-patient correlation. Logistic
regression was used to assess the association of a series of patients’
characteristics with bleeding; Odds Ratios (OR) and 95%CI were
computed. ROC curve analysis was used to identify the optimal
cut offs for the association of platelets counts and bleedings. Stata
13 (StataCorp, College Station, TX, USA) was used for computa-
tion. Two-sided P<0.05 was considered statistically significant.
Results
Not all data were available for all investigated patients,
and results described below report the number of investi-
gated cases for which data were available. In case the num-
ber of investigated patients is not reported, it is intended
that all patients were studied.
Womens’ base-line characteristics 
One hundred and eighty-one women with 13 different
forms of IT who had a total of 339 pregnancies were inves-
tigated retrospectively by 45 centers in 20 countries. In 169
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Table 1. Diagnosis and base-line features of investigated women with different forms of inherited thrombocytopenia who had one or more pregnancies. 
Disorder N. of Median N. of patients with a Median platelet WHO bleeding N. of N. of N. of N. of 
(abb., women age in years previous diagnosis/count before pregnancy scale*, N. patients patients patients patients
phenotype at diagnosis, medical treatment/ x109/L, 25th-75th of patients with a receiving receiving with EBBT with AEB 
MIM number) 25th-75th percentile splenectomy for percentile history of spontaneous surgery prophylactic at surgery at surgery
immune bleeding of grades platelet N. of  evaluated N. of 
thrombocytopenia 0-1-2-3-4 transfusions patients evaluated
N. of  evaluated evaluated
patients
MYH9-related 98 31, 19-42 41/32/11 40, 23-64 39-21-30-5-3 67 26 (67) 9 (67) 20 (67)
disease  
(MYH9-RD, 600208) 
ANKRD26-related 23 21, 11-40 8/6/3 54, 30-84 6-4-7-3-3 12 2 (11) 0 (11) 1 (11)
thrombocytopenia 
(ANKRD26-RT, 188000)
Biallelic 13 33, 26-36 3/3/1 50, 23-92 5-0-5-2-1 8 1 (7) 1 (7) 2 (7)
Bernard-Soulier 
syndrome (bBSS, 231200)
Monoallelic 24 31, 19-41 1/1/0 86, 77-111 12-4-3-5-0 13 1 (13) 0 (13) 3 (13)
Bernard-Soulier syndrome 
(mBSS, 231200)
ACTN1-related 9 21, 17-40 0/0/0 77, 65-94 2-3-2-2-0 4 0 (4) 0 (4) 2 (4)
thrombocytopenia
(ACTN1-RT, 615193)
Familial platelet 4 37, 26-38 1/1/0 116, 93-138 0-0-3-0-1 2 0 (2) 0 (2) 1 (2)
disorder and 
predisposition 
to acute myelogenous leukemia 
(FPD/AML, 601399)
ITGB3-related 3 16, 11-37 0/0/0 78, 65-114 1-0-0-2-0 3 3 (3) 0 (3) 0 (3)
thrombocytopenia 
(ITGB3-RT, 187800)
Platelet-type 2 27, 27-28 1/0/0 80, 30-130 0-1-0-0-1 1 0 (1) 0 (1) 1 (1)
von Willebrand disease 
(VWDP, 177820)
Gray platelet 1 13 1/1/0 65 0-0-0-1-0 1 1 (1) 0 (1) 0 (1)
syndrome 
(GPS, 139090)
FLNA-related 1 23 0/0/0 43 1-0-0-0-0 1 0 (1) 0 (1) 0 (1)
thrombocytopenia 
(FLNA-RT, nd)
TUBB1-related 1 4 1/0/0 100 0-1-0-0-0 1 0 (1) 0 (1)
thrombocytopenia
(TUBB1-RT, 613112) 0 (1)
Velocardiofacial 1 34 0/0/0 75 0-1-0-0-0 1 0 (1) 0 (1) 0 (1)
syndrome 
(VCFS, 192430)
CYCS-related 1 25 0/0/0 35 0-1-0-0-0 1 0 (1) 0 (1) 0 (1)
thrombocytopenia  
(CYCS-RT, 612004)
Total 181 29 (19-39) 57/44/15 57 (30-82) 66-36-50-20-9 114 34 (112) 10 (112) 30 (112)
*World Health Organization bleeding scale:  grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss;  EBBT: excessive bleeding
requiring blood transfusion; AEB: all excessive bleedings; 25th-75th: 25th-75th percentiles.
women, diagnoses were confirmed by the identification of
mutations in the candidate genes, while in 12 subjects a
diagnosis of MYH9-RD was made on the basis of a positive
immunofluorescence test for the distribution of MYH9 pro-
tein in neutrophils.8 Of note, 18 of 24 women with the diag-
nosis of mBSS had the p.Ala156Val substitution in GPIb
alpha (Bolzano mutation).6
Patients’ features before pregnancy are reported in Table
1. A feature common to many investigated patients was the
difficulty of making a correct diagnosis of IT, as shown by
the observation that 57 subjects were initially misdiagnosed
with immune thrombocytopenia. Forty-four of these
women received unnecessary treatment, including splenec-
tomy in 15 cases. Difficulties in diagnosis is also demon-
strated by the finding that the inherited origin of thrombo-
cytopenia was recognized in adulthood in most cases, with
a mean age at diagnosis of 30 years. These findings under-
score the need to maintain a high index of suspicion for ITs
in the evaluation of patients with thrombocytopenia.11
Thrombocytopenia was on average moderate, with a
mean platelet count of 60 x 109/L in the whole case series
and a mean platelet count higher than 45 x 109/L in all dis-
Pregnancy in inherited thrombocytopenias
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orders for which more than one patient was examined.
However, severely reduced platelet counts were observed
in a few cases. In this regard, it is important to note that
platelet counts were measured by electronic cell counters
and that these instruments are known not to recognize very
large platelets.12 It is, therefore, expected that the degree of
thrombocytopenia was overestimated in patients with
inherited macrothrombocytopenias, especially those with
MYH9-RD and bBSS who typically have giant platelets.
Spontaneous bleeding tendency before pregnancy was on
average mild. WHO grade 3 and 4 bleeding were reported
in only 20 and 9 of 181 subjects, respectively. 
Perioperative AEB and EBBT were reported in 30 and 10
of 112 women receiving surgery, respectively.
Gestations
No variation in severity of the pre-existing bleeding ten-
dency was reported during pregnancy (data not shown). 
The course of gestation was uneventful in 304 cases,
while miscarriage was reported in 34 pregnancies (10.1%,
95%CI: 7.2-14.0). One therapeutic interruption of pregnan-
cy because of fetal malformation was reported. The inci-
dence of miscarriage is superimposable to that observed in
a large population of white women in the US (10.2%).13
Pregnancy loss occurred in the first trimester in 29 cases, in
the second in 5 cases, and in the third in one case. 
Pre-term birth was recorded for 30 pregnancies (9.9%,
95%CI: 6.8-13.7), and thus the frequency of this event was
not significantly different from that observed in a general
population of Western countries (7.4%).14 All pre-term
deliveries occurred at a gestational age of 36 or 37 weeks.
Newborns
Diagnostic definition was possible in 278 newborns: 156
were affected by ITs, while 122 were unaffected.
Comparison of platelet counts in the 126 affected new-
borns for which this information was available with base-
line platelet counts in their mothers revealed that the degree
of thrombocytopenia was similar, although the small
observed difference was statistically significant (mean
platelet count in the newborns 69 x 109 platelets/L, in the
mothers 58 x 109/L; P=0.020).
Bleeding signs consisting of petechiae were observed in 5
affected neonates, while fatal cerebral hemorrhages were
P. Noris et al.
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Table 2. Characteristics of pregnancy,  delivery and newborns in women with inherited thrombocytopenias. The number of investigated patients is reported (in
brackets) in case of missing data.
Disorders N. of Median Median N. of term/ N. of vaginal N. of N. of N. of N. of N. of N. of 
pregnancies/ age in platelet preterm deliveries/ deliveries with  deliveries withdeliveries with deliveries with healthy affected
miscarriages years at count at deliveries cesarean general/ prophylactic EBBT, % AEB, % newborns newborns
delivery,  delivery (N. of sections spinal  or platelet incidence, CI incidence, CI affected by with
25th-75th x109/L, evaluated (N. of epidural/no transfusion (N. of (N. of the mother bleedings 
percentile 25th-75th deliveries) evaluated anesthesia (N. of evaluated evaluated disorder (N. of 
percentile deliveries) (N. of evaluated deliveries) deliveries) (N. of evaluated 
(N. of evaluated deliveries) evaluated babies)
evaluated deliveries) babies)
deliveries)
MYH9-RD 185/21 28, 24-32 60, 34-80 142/20 94/69 54/34/73 31 13, 8.3, 4.5- 24, 15.3, 10.1-22 58/94 6 (94)
(86) (162) (163) (163) (161) 13.8 (156) (156) (152)
ANKRD26-RT 48/6 29, 25-30 34, 28-76 41/1 27/15 5/2/27 4 3, 7.1, 1.4- 5, 11.9, 17/23 0 (23)
(26) (42) (42) (34) (42) 19.4  (42) 3.9-25.6 (42) (40)
bBSS 22/1 32, 28-35 40, 26-65 16/5 8/13 9/4/7 6 1, 4.7, 0.1-23.8  3, 14.2, 3-36.3 12/3 (15) 0 (3)
(15) (21) (21) (20) (21) (21) (21)
mBSS 42/3 29, 25-34 86, 66-105 37/2 29/10 6/4/28 0 1, 2.5, 0.1-13.4 5, 12.8, 4.2- 19/18 1(18)
(33) (39) (39) (38) (39) (39) 27.4 (39) (37)
ACTN1-RT 18/1 24, 22-26 72, 55-88 17/0 17/0 0/0/17 0 0, 0, 0-19.5 0, 0, 0-19.5 6/11 0 (11)
(11) (17) (17) (17) (17) (17) (17)
FPD/AML 9/2 27, 21-29 92, 80-105 7/0 4/3 0/1/4 1 1, 14.2, 0.3- 1, 14.2, 0.3- 3/3 0(3)
(4) (7) (7) (5) (7) 57.8 (7) 57.8 (7) (6)
ITGB3-RT 3/0 28, 24-29 82, 58-110 (3) 3/0 (3) 0/3 (3) 1/0/0 (1) 2 (3) 0, 0, 0-70.7 (3) 0, 0, 0-70.7 (3) 1/2 (3) 0 (2)
VWDP 5/0 30, 29-32 110, 58-113 (5) 4/1 (5) 3/2 (5) 2/0/3 (5) 0 (5) 1, 20, 0.5-71.6 (5)3, 60, 14.6-94.7 (5) 3/0 (3) 0 (0)
GPS 3/1 25, 25-28 47, 40-55 (2) 2/0 (2) 2/0 (2) 2/0/0 (2) 2 (2) 0, 0, 0-84.1 (2) 1, 50, 1.2-98.7 (2) 2/0 (2) 0 (0)
FLNA-RT 1/0 28 82 (1) 1/0 (1) 1/0 (1) 0/0/1 (1) 0 (1) 0, 0, 0-97.5  (1) 0, 0, 0-97.5 0/1 (1) 0 (1)
(1) (1)
TUBB1-RT 1/0 39 48 (1) 0/1 (1) 0/1 (1) 1/0/0 (1) 0 (1) 0, 0, 0-97.5 (1) 0, 0, 0-97.5 (1) 0/0 (0) 0 (0)
VCFS 1/0 33 (0) 1/0 (1) 1/0 (1) 0/1/0 (1) 0 (1) 0, 0, 0-97.5 (1) 0, 0, 0-97.5 (1) 0/1 (1) 0 (1)
CYSC-RT 1/0 28 50 (1) 1/0 (1) 1/0 (1) 0/0/1 (1) 0 (1) 0, 0, 0-97.5 (1) 0, 0, 0-97.5 (1) 1/0 (1) 0 (0)
TOTAL 339/35 28, 25-32 65, 37-85 272/30 187/116 80/46/161 46 (301) 20, 6.7, 4.1- 42, 14.1, 10.4- 122/156 () 7 (156)
(188) (302) (303) (289) 10.2 (296) 18.6 (296) 278
EBBT: excessive bleeding requiring blood transfusion; AEB: all excessive bleedings; 25th-75th: 25th-75th percentiles; CI: 95% confidence intervals.
reported in 2 infants born by vaginal delivery to 2 MYH9-
RD mothers with greatly reduced platelet counts (12 and 16
x 109/L, respectively). Platelet count was severely reduced in
one newborn (7 x 109/L) with the same MYH9mutation as
the mother, while neither testing for MYH9-RD nor a
platelet count were carried out in the other neonate because
he died shortly after birth.
Deliveries 
Table 2 describes maternal characteristics at delivery as
well as management of childbirth and bleeding events.
Platelet count at delivery was available in 188 cases, and
comparison with base-line non-pregnant platelet count
revealed mild differences (mean platelet count before preg-
nancy 56 x 109/L, at delivery 65 x 109/L; P=0.071). Thus,
only limited changes in platelet count are expected to occur
during pregnancy in patients with ITs. 
Prophylactic platelet transfusions were given in prepara-
tion for delivery in 46 of 301 evaluable cases, while other
prophylactic treatments, consisting of steroids, desmo-
pressin, tranexamic acid or recombinant activated factor
VII, were given in 9, 5, 2 and one case, respectively. 
Mean platelet count at delivery was lower in women
given prophylactic platelet transfusions than in women not
receiving this treatment (40 vs. 69 x 109/L; P<0.001). Similar
results were obtained when baseline non-pregnant platelets
counts were considered (38 vs. 65 x 109/L; P<0.001). This
indicates that platelet count may have been a parameter
used by physicians to determine the need for prophylactic
platelet transfusion. 
One hundred and sixteen of 303 births were by caesarean
section. In the 289 deliveries for which information on pain
control was available, general anesthesia was performed in
80 cases (27.7%), and spinal or epidural anesthesia in 46
(15.9%). No bleeding complications related to these proce-
dures were reported. 
AEB occurred in 42 cases (14.2% of deliveries, 95%CI:
10.4-18.7) and EBBT in 20 cases (6.8% of deliveries, 95%CI:
4.17-10.2). In case of EBBT, platelet transfusions were given
in 6 deliveries, red cell transfusions in 9 and both red blood
cell and platelet concentrates in 5. Since the incidence of
abnormal bleeding at delivery in the normal population, as
evaluated by the amount of blood loss, is 3-7% in high
resource countries,2 the frequency of AEB appears to be
higher in ITs than in the general population. Comparison of
the need for red blood cell transfusion in our case series is
possible with that observed in the general population: fif-
teen deliveries in women with ITs required erythrocyte
transfusions (5.06%, 95%CI: 2.8-8.0), while the need for
this treatment ranged from 0.5 to 1.2% in non-thrombocy-
topenic women.2,15,16 Altogether, these results indicate that
bleeding risk at delivery is increased in ITs.
No women died from complications of childbirth or
required hysterectomy to stop bleeding. 
Correlations between mothers’ features and bleedings
at delivery
Some predictors of AEB and EBBT at delivery were iden-
tified (Table 3). Considering EBBT at delivery, a trend
towards statistically significant association was found with
EBBT at previous surgery (OR 4.7, 95%CI: 0.8-26.9), while
a significant correlation was found with a history of grade
3 or 4 (OR 5.32, 95%CI: 1.22-23.11) and grade 4 (OR 24.50,
95%CI: 4.75-126.41) of WHO bleeding scale. 
EBBT was also significantly associated with a base-line
platelet count in the lowest tertile, and a trend towards sig-
nificance was found between EBBT and platelet count in
the lowest tertile at delivery (platelets >49 x 109/L). ROC
analysis identified platelet counts of 44 and 50 x 109/L as the
optimal cut offs of platelet counts before pregnancy and at
delivery, respectively, for the identification of patients with
a higher risk for EBBT. The incidence of EBBT in mothers
with platelet counts below these cut-off values before preg-
nancy and at delivery was 3.92 (95%CI: 1.43-10.70) and
7.61 (95%CI: 1.55-37.60) times higher, respectively, than in
patients with higher platelet counts. Both differences were
statistically significant. 
EBBT was not less frequent in vaginal deliveries than in
caesarean sections and was not reduced in women who
received prophylactic platelet transfusions prior to delivery.
Table 2 shows that the incidence of bleeding requiring
blood transfusion was not significantly different in different
forms of IT. However, this finding is reliable for MYH9-RD,
ANKRD6-RT, bBSS, mBSS and ACTN1-related thrombocy-
topenia (ACTN1-RT) because of the high number of inves-
tigated deliveries, while it is not dependable for all other
disorders because of the low number of observed child-
births.
A history of surgical bleeding and lower platelet counts
also correlated with AEB, though to a lesser extent than
with EBBT. As with EBBT, other examined maternal char-
acteristics did not predict AEB at delivery. 
Discussion
Inherited thrombocytopenias have long been considered
exceedingly rare, but recent advances have facilitated diag-
nosis and greatly increased the number of reported
patients.17 Although population studies have not yet been
performed, it has recently been calculated that the preva-
lence of ITs in Italy is at least 2.7 in 100,000.18 The improved
knowledge of ITs has also changed our view of their clinical
picture. It has been shown that bleeding tendency is mild in
the majority of patients and spontaneous life-threatening
hemorrhage is uncommon/rare.11 Nevertheless, hemostatic
challenges always need careful attention. Pregnancy and
delivery are especially critical because both mothers and
affected newborns are at risk of hemorrhage. However,
published data are insufficient to provide an evidence-based
approach to management during pregnancy and delivery.
The present study on 339 pregnancies in 181 women with
13 different ITs provides, for the first time, the opportunity
to systematically examine this topic in detail.
Results of our study on the one hand suggest that the
course of pregnancy in ITs does not differ from that of
healthy women; on the other hand, the risk of bleeding
with childbirth appears to be increased in both mothers and
neonates.
Neither thrombocytopenia nor bleeding tendency wors-
ened during pregnancy. The incidence of pregnancy loss
was superimposable to that observed in healthy women,
and the incidence of pre-term birth was not increased in
women with ITs. No intrauterine bleeding was reported in
the 156 fetuses who inherited IT. However, antepartum
gastrointestinal19 and intracranial bleedings20 with fatal con-
sequences have been previously described in the fetuses of
2 bBSS mothers. A risk of major bleeding in utero must,
therefore, be borne in mind, though such events were not
observed in our study cohort. Regarding delivery-related
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neonatal bleedings, our data indicate that the risk is low,
although fatal hemorrhages may occur. Indeed, only 7 of
156 affected newborns had bleeding. In 5 cases, bleeding
consisted of petechiae, but 2 neonates, both born by vaginal
delivery to mothers with severe thrombocytopenia due to
MYH9-RD, died of cerebral hemorrhage. To our knowl-
edge, delivery-related fatal intracranial hemorrhages have
not been previously reported in neonates with ITs. The
small number of neonates affected by ITs other than
MYH9-RD does not allow us to exclude a risk of severe
neonatal hemorrhage with these conditions, though none
were observed in our series. Similarly, we cannot conclude
that vaginal delivery is associated with a greater risk of
neonatal hemorrhage, because this type of birth was chosen
in the vast majority of MYH9-RD women, as well as in
other forms of ITs. Thus, infants delivered vaginally by
severely thrombocytopenic women with MYH9-RD must
be considered at risk for intracranial bleeding; we cannot
exclude the possibility that other forms of IT or caesarean
section may expose newborns to similar risk. The incidence
of delivery-related maternal bleeding in our case series
ranged from 6.8% to 14.2% depending on the criterion
used for defining abnormal bleeding. Comparison with
healthy women is difficult, because most commonly used
definitions of partum-related hemorrhages in the general
population rely on the amount of blood loss (>500 mL for
vaginal deliveries, and >750-1500 mL for caesarean births),2
but this information was not available for the majority of
our patients. Instead, we adopted two different criteria for
increased bleeding: one based on the need to give blood
products (EBBT), the other taking into account not only
blood transfusions, but also the judgment of the obstetri-
cian that bleeding was excessive (AEB). The former defini-
tion may underestimate the occurrence of hemorrhages as
defined by the entity of blood loss, because it is conceivable
that not all women losing more than 500 mL of blood after
vaginal delivery or more than 750 mL after caesarean sec-
tion received blood transfusions. Also the latter definition
risks underestimating the frequency of bleedings because it
includes a subjective assessment and it has been shown that
P. Noris et al.
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Table 3. Correlations between mother characteristics and bleeding at delivery.
Mothers’ characteristics N.  of EBBT at delivery AEB at delivery
deliveries Events OR 95% CI P-value Events OR 95% CI P-value
EBBT at previous surgery 17 4 4.77 0.85-26.87 0.08 6 1.45 0.36-5.83 0.60
AEB at previous surgery 56 6 2.06 0.69-6.12 0.20 15 2.75 1.15-6.62 0.023
Tertiles of WHO bleeding scale* 0.08 0.31
1st (0-0) 101 3 1 - - 11 1 - -
2nd (1-2) 145 10 2.42 0.65-8.96 0.19 20 1.31 0.53-3.21 0.56
3rd (3-4) 50 7 5.32 1.22-23.11 0.026 11 2.31 0.77-6.97 0.13
WHO bleeding scale* <0.001 0.06
0 101 3 1 - - 11 1 - -
1 59 2 1.15 0.19-7.06 0.88 6 0.93 0.30-2.83 0.30
2 86 8 3.35 0.87-12.92 0.08 14 1.59 0.60-4.20 0.60
3 36 1 0.93 0.09-9.20 0.95 4 1.02 0.29-3.61 0.97
4 14 6 24.50 4.75-126.41 <0.001 7 8.18 1.80-37.29 0.007
Tertiles of platelet count at delivery 0.09 0.40
1st (<49 x 109/L) 65 7 1 - - 11 1 - -
2nd (49-80 x 109/L) 66 1 0.12 0.01-1.29 0.080 6 0.13 0.01-1.09 0.06
3rd (> 80 x 109/L) 56 2 0.28 0.04-2.00 0.20 8 0.31 0.06-1.54 0.15
Tertiles of platelet count before pregnancy 0.11 0.60
1st (<39 x 109/L) 101 10 1 - - 17 1 - -
2nd (39-77 x 109/L) 96 8 0.83 0.30-2.27 0.71 14 0.84 0.36-1.96 0.69
3rd (>77 x 109/L) 99 2 0.19 0.04-0.90 0.037 11 0.62 0.24-1.59 0.31
Platelet count before 117 14 3.92 1.43-10.70 0.008 23 2.06 0.99-4.28 0.053
pregnancy < 44 x 109/L
Platelet count at delivery 69 8 7.61 1.55-37.60 0.012 14 2.49 1.02-6.02 0.046
< 50 x 109/L 
Diagnosis of biallelic 21 1 0.67 0.08-5.58 0.71 3 1.01 0.29-3.47 1.00
Bernard-Soulier syndrome
Primipara 168 14 1.85 0.71-4.84 0.21 27 1.44 0.79-2.63 0.23
Tertiles of age at pregnancy 0.81 0.31
1st (15-26) 102 8 1 - - 18 1 - -
2nd (27-31) 103 7 0.86 0.33-2.26 0.75 15 0.80 0.35-1.80 0.58
3rd (32-41) 91 5 0.68 0.22-2.15 0.51 9 0.51 0.22-1.21 0.12
Prophylactic platelet 44 3 1.01 0.30-3.42 0.99 8 1.47 0.62-3.49 0.38
transfusion before delivery
Vaginal delivery 183 11 0.74 0.31-1.79 0.50 25 0.89 0.44-1.83 0.76
*World Health Organization bleeding scale: grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss; EBBT: excessive bleed-
ing requiring blood transfusion; AEB: all excessive bleedings; OR: Odds Ratio; CI: confidence intervals. 
visual estimation tends to under-evaluate blood loss at
delivery with respect to more accurate measurements.21
Since the incidence of increased bleeding at delivery in the
general population ranges from 3% to 7%,2 AEB in our case
series was higher than normal, while EBBT was at the
upper limit of normal range. However, the observation that
red blood cell transfusions at delivery were given much
more frequently in our patients (5% of deliveries) than in
the general population (0.5-1.2%) strongly suggests that
bleeding risk is increased in ITs.  
Because of this, we searched for mothers’ parameters able
to predict delivery-related bleedings. EBBT at childbirth
was more frequent in women with higher grades of the
WHO bleeding scale before pregnancy, and a trend toward
statistical significance was found between EBBT at delivery
and EBBT at previous surgeries. Also the degree of throm-
bocytopenia before pregnancy and at delivery was related
to EBBT, although with different degrees of statistical signif-
icance. Based on this finding, we searched for the cut-off
value of platelet count able to predict EBBT by ROC curve
analysis, and found that platelet count less than 50 x 109/L
at delivery and less than 44 x 109/L before pregnancy were
significantly associated with higher frequency of hemor-
rhage requiring blood products. Thus, the bleeding tenden-
cy before pregnancy and the degree of thrombocytopenia
are both important to predict severe bleeding at childbirth.
Of note, experts’ recommendations for management of
pregnancy in patients with immune thrombocytopenia
identified platelet count 50 x 109/L as the minimum value
required for safe delivery.22,23
Broadly similar results were obtained in the search for
correlations between AEB at delivery in the mothers and
their previous bleeding tendency as well as their platelet
counts. However, the risk deriving from unfavorable fea-
tures was lower and had lower statistical significance than
for EBBT, probably because the definition of AEB includes
a subjective judgment of milder bleeding events.
No other investigated maternal characteristics predicted
increased bleeding at delivery. Based on the common
notion that severe hemorrhages are frequent on the occa-
sion of hemostatic challenges in patients with bBSS and the
previously published data on delivery in these patients,4 it is
surprising that bleeding events at childbirth in our case
series were no more frequent in bBSS than in other forms
of IT. This unexpected finding could have several explana-
tions. First, the base-line bleeding tendency in our bBSS
women was milder than that observed in other series of
unselected bBSS patients, as shown by the observation that
WHO grade 3 and 4 bleeding were reported only in 3 of our
13 women, while they were described in 7 of 10 patients of
a previous case series.24 It may be that our group of bBSS
patients was enriched in forms with mild bleeding tenden-
cy because some women with severe bBSS have undergone
hysterectomy for heavy menstruation or have been discour-
aged from having a pregnancy by the fear of bleeding at
delivery. Moreover, the frequency of prophylactic platelet
transfusions in bBSS women was twice that of women
with other ITs, and this may have masked a higher risk of
bleeding. The observation that only one AEB (not requiring
blood products) was reported in 15 deliveries of bBSS
patients not preceded by prophylactic platelet transfusions
supports the hypothesis that giving platelets in preparation
for delivery may be unnecessary in women with mild
forms of bBSS. Finally, the previous systematic review,
which was based on case reports and, therefore, was highly
susceptible to reporting bias, could have overestimated
bleeding risk at delivery. 
Another surprising finding was the similar incidence of
increased bleeding at delivery in mothers receiving or not
receiving prophylactic platelet transfusions, in that this
result might suggest that platelet transfusions were ineffec-
tive. However, the observation that platelet count was
lower in women given transfusions provides a credible
alternative explanation and suggests that prophylactic
platelet infusions were effective in reducing the incidence of
hemorrhage.
Our study has some limitations. First, only a small num-
ber of eligible patients with some forms of IT were identi-
fied by the participating centers (Table 1), likely reflecting
the rarity of these disorders. Creation of larger international
registries is required to further improve knowledge of preg-
nancy outcomes in these rare disorders. Another limitation
derives from the failure of automated cell counters to iden-
tify very large platelets and the resulting underestimation of
platelet count in inherited macrothrombocytopenias, espe-
cially bBSS and MYH9-RD.12 It is thus likely that the degree
of thrombocytopenia in these conditions was overestimat-
ed in our study. Moreover, data were missing in a relevant
number of patients enrolled in the study, a limitation inher-
ent to retrospective investigations. Finally, we compared
the outcome of pregnancy in women with ITs with that
reported in general population. Comparison with non-
thrombocytopenic women from these same institutions
from the same time periods would be more appropriate,
but obtaining the required information from 45 centers in
20 countries seemed to us a hopeless undertaking.
In conclusion, our study showed that delivery-related
bleeding risk is higher in ITs than in the general population
for both mothers, who may have blood loss requiring blood
transfusions, and affected newborns, who may rarely pres-
ent with fatal intracranial hemorrhage. Nevertheless, deliv-
ery occurs without bleeding complications in the vast
majority of mothers and neonates. Our study also identified
the degree of thrombocytopenia and a history of severe
bleeding tendency in the mother as potentially useful
parameters to predict the risk of delivery-related bleedings.  
Collaborators
In alphabetical order Sophie Bayart,1 Anne Bauters,2
Schéhérazade Benabdallah-Guedira,3 Françoise Boehlen,4-5
Jeanne-Yvonne Borg,6 Roberta Bottega,7 James Bussel,8
Daniela De Rocco,9 Emmanuel de Maistre,10 Michela Faleschini,9
Emanuela Falcinelli,11 Silvia Ferrari,12 Alina Ferster,13 Tiziana
Fierro,11 Dominique Fleury,14 Pierre Fontana,4-5 Chloé James,15
Francois Lanza,16 Véronique Le Cam Duchez,6 Giuseppe
Loffredo,17 Pamela Magini,18 Dominique Martin-Coignard,19
Fanny Menard,20 Sandra Mercier,21 Annamaria Mezzasoma,11
Pietro Minuz,22 Ilaria Nichele,23 Lucia D. Notarangelo,24 Tommaso
Pippucci,18 Gian Marco Podda,25 Catherine Pouymayou,26 Agnes
Rigouzzo,27 Bruno Royer,28 Pierre Sie,29 Virginie Siguret,30 Catherine
Trichet,31 Alessandra Tucci,32 Béatrice Saposnik,33 Dino Veneri22.
1Service d’Hémostase Bio-Clinique, Centre Régional de traitement
des maladies hémorragiques de Rennes-Bretagne, CHU de
Rennes, Rennes, France; 2Institut d’Hématologie-Transfusion, Pôle
Biologie Pathologie Génétique, CHRU Lille, France; 3Université
Mohamed V Rabat, Faculté de Médecine et de Pharmacie, Hôpital
Avicenne, Rabat, Morocco; 4Division of Angiology and
Haemostasis, Department of Medical Specialisations, Faculty of
Medicine and University Hospitals of Geneva, Geneva,
Switzerland; 5Geneva Platelet Group, Faculty of Medicine,
Pregnancy in inherited thrombocytopenias
haematologica | 2014; 99(8) 1393
University of Geneva, Geneva, Switzerland; 6CHU Charles
Nicolle, Unité Hémostase-Hématologie, Rouen, France; 7Institute
for Maternal and Child Health – IRCCS Burlo Garofolo, Trieste,
Italy; 8Weill Medical College of Cornell University, New York,
NY, USA; 9Department of Medical Sciences, University of Trieste,
Trieste, Italy; 10Service d’hématologie Biologie, Centre Hospitalo-
Universitaire Dijon, France; 11Department of Internal Medicine,
University of Perugia, Perugia, Italy; 12Department of Medicine-
DIMED; University of Padova Medical School, Padova, Italy;
13Unité d’Hémato-Oncologie pédiatrique, Hôpital Universitaire
des Enfants Reine Fabiola, Bruxelles, Belgique; 14Service de
Néphrologie, CH Valenciennes, Valenciennes, France;
15Laboratoire d'Hématologie and National Reference Centre on
Inherited Platelet Disorders, CHU Haut Lévêque, Pessac, France;
16INSERM UMR-S949/EFS-Alsace, Strasbourg, France;
17Department of Oncology, Azienda Santobono-Pausilipon,
Pausilipon Hospital, Napoli, Italy; 18Genetica Medica,
Dipartimento di Scienze Mediche Chirurgiche, Policlinico
Sant'Orsola-Malpighi - University of Bologna, Bologna, Italy;
19Laboratoire de Génétique, CH Le Mans, France; 20Centre
Hospitalier de la côte basque, Bayonne, France;21Service de
Génétique Clinique, Centre de Référence Anomalies du
Développement du Grand Ouest, CHU Rennes-Hôpital Sud,
Rennes, France; 22Department of Medicine and Haematology,
University Hospital of Verona, Verona, Italy; 23Department of Cell
Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy;
24Department of Pediatrics, University of Brescia, Brescia, Italy;
25Medicina III, Ospedale San Paolo, Dipartimento di Scienze della
Salute, Università degli Studi di Milano, Italy; 26Laboratoire
d’Hématologie and National Reference Centre on Inherited Platelet
Disorders, CHU La Timone, Marseille, France; 27AP-HP, Armand
Trousseau children Hospital, Department of Anesthesiology, Paris,
France; 28Hématologie clinique et thérapie cellulaire, CHU Amiens,
France; 29Laboratoire d'Hématologie and National Reference
Centre of Inherited Platelet Disorders, CHU Rangueil, Toulouse,
France; 30Service d' Hématologie Biologique, CHU Hôpital
Européen Georges Pompidou, Paris, France; 20Service de Biologie
Clinique Secteur Hématologie,  CH Victor Dupouy,  Argenteuil,
France; 32Hematology Unit, Spedali Civili Hospital and University
of Brescia, Brescia, Italy; 33National Reference Centre on Inherited
Platelet Disorders and Service d’Hématologie Biologique, CHU
Robert Debré and Paris 7 Denis Diderot University, Paris, France. 
Contribution: Collaborators contributed to characterization or
collection of patients, had the opportunity to revise the manuscript
and approved it.
Funding
This work was supported by a grant from Telethon Foundation,
Italy (no. GGP10089).
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
P. Noris et al.
1394 haematologica | 2014; 99(8)
References
1. Edhi MM, Aslam HM, Naqvi Z, Hashmi H.
Post partum hemorrhage: causes and man-
agement. BMC Res Notes. 2013;6(1):236.
2. Knight M, Callaghan WM, Berg C,
Alexander S, Bouvier-Colle MH, Ford JB, et
al. Trends in postpartum hemorrhage in high
resource countries: a review and recommen-
dations from the International Postpartum
Hemorrhage Collaborative Group. BMC
Pregnancy Childbirth. 2009 Nov 27;9:55.
3. Bolton-Maggs PH, Chalmers EA, Collins
PW, Harrison P, Kitchen S, Liesner RJ, et al. A
review of inherited platelet disorders with
guidelines for their management on behalf
of the UKHCDO. Br J Haematol. 2006;135
(5):603-33. 
4. Peitsidis P, Datta T, Pafilis I, Otomewo O,
Tuddenham EG, Kadir RA. Bernard Soulier
syndrome in pregnancy: a systematic
review. Haemophilia. 2010;16(4):584-91. 
5. Hussein BA, Gomez K, Kadir RA. May-
Hegglin anomaly and pregnancy: a system-
atic review. Blood Coagul Fibrinolysis.
2013;4(5):554-61
6. Noris P, Perrotta S, Bottega R, Pecci A,
Melazzini F, Civaschi E, et al. Clinical and
laboratory features of 103 patients from 42
Italian families with inherited thrombocy-
topenia derived from the monoallelic
Ala156Val mutation of GPIb (Bolzano
mutation). Haematologica. 2012;97(1):82-8.
7. Pippucci T, Savoia A, Perrotta S, Pujol-Moix
N, Noris P, Castegnaro G, et al. Mutations in
ANKRD26 are responsible for a frequent
form of inherited thrombocytopenia: analy-
sis of 78 patients from 21 families. Blood.
2011;117(24):6673-80.
8. Savoia A, De Rocco D, Panza E, Bozzi V,
Scandellari R, Loffredo G, et al. Heavy chain
myosin 9-related disease (MYH9 -RD): neu-
trophil inclusions of myosin-9 as a pathog-
nomonic sign of the disorder. Thromb
Haemost. 2010;103(4):826-32.
9. Miller AB, Hoogstraten B, Staquet M,
Winkler A. Reporting results of cancer treat-
ment. Cancer. 1981;47(1):207-14.
10. American College of Obstetrics and
Gynecology practice bulletin: Clinical
Management Guidelines for Obstetricians-
Gynecologists number 76, October 2006:
Postpartum Hemorrhage. Obstet Gynecol.
2006;108(4):1039-47.
11. Balduini CL, Savoia A, Seri M. Inherited
thrombocytopenias frequently diagnosed
in adults. J Thromb Haemost. 2013;11(6):
1006-19.
12. Noris P, Klersy C, Gresele P, Giona F,
Giordano P, Minuz P, et al. Platelet size for
distinguishing between inherited thrombo-
cytopenias and immune thrombocytopenia:
a multicentric, real life study. Br J Haematol.
2013;162(1):112-9.
13. Mukherjee S, Velez Edwards DR, Baird DD,
Savitz DA, Hartmann KE. Risk of miscar-
riage among black women and white
women in a U.S. Prospective Cohort Study.
Am J Epidemiol. 2013;177(11):1271-8. 
14. Beck S, Wojdyla D, Say L, Betran AP,
Merialdi M, Requejo JH, et al. The world-
wide incidence of preterm birth: a system-
atic review of maternal mortality and mor-
bidity. Bull World Health Organ. 2010;
88(1):31-8.
15. Roberts CL, Ford JB, Algert CS, Bell JC,
Simpson JM, Morris JM. Trends in adverse
maternal outcomes during childbirth: a
population-based study of severe maternal
morbidity. BMC Pregnancy Childbirth.
2009;25 (9):7.
16. Kuklina EV, Meikle SF, Jamieson DJ,
Whiteman MK, Barfield WD, Hillis SD, et al.
Severe obstetric morbidity in the United
States: 1998-2005. Obstet Gynecol. 2009;
113(2 Pt 1):293-9. 
17. Balduini CL, Savoia A. Genetics of familial
forms of thrombocytopenia. Hum Genet.
2012;131(12):1821-32. 
18. Balduini CL, Pecci A, Noris P. Inherited
thrombocytopenias: the evolving spectrum.
Hamostaseologie. 2012;32(4):259-70. 
19. Peng TC, Kickler TS, Bell WR, Haller E.
Obstetric complications in a patient with
Bernard–Soulier syndrome. Am J Obstet
Gynecol. 1991;165(2):425-6.
20. Fujimori K, Ohto H, Honda S, Sato A.
Antepartum diagnosis of fetal intracranial
hemorrhage due to maternal Bernard–
Soulier syndrome. Obstet Gynecol. 1999; 94
(5 Pt 2):817-9.
21. Stafford I, Dildy GA, Belfort MA. Visually
estimated and calculated blood loss in vagi-
nal and cesarean delivery. Am J Obstet
Gynecol. 2008;199(5):519.e1-7.
22. Letsky EA, Greaves M. Guidelines on the
investigation and management of thrombo-
cytopenia in pregnancy and neonatal alloim-
mune thrombocytopenia. Maternal and
Neonatal Haemostasis Working Party of the
Haemostasis and Thrombosis Task Force of
the British Society for Haematology. Br J
Haematol. 1996; 95(1):21-6
23. Gill KK, Kelton JG. Management of idio-
pathic thrombocytopenic purpura in preg-
nancy. Semin Hematol. 2000;37(3):275-89.
24. Savoia A, Pastore A, De Rocco D, Civaschi
E, Di Stazio M, Bottega R, et al. Clinical and
genetic aspects of Bernard-Soulier syn-
drome: searching for genotype/phenotype
correlations. Haematologica. 2011;96(3):
417-23.
